Stopping Heavy Cannabis Use Was Linked to Poorer Sleep. The Second Night Looked Worse. ↗
In the first 48 hours after stopping heavy cannabis use, lab sleep was shorter, lighter, and more fragmented, with bigger gaps versus controls on night two.
Browse more cannabis research, findings, methods, and limitations.
In the first 48 hours after stopping heavy cannabis use, lab sleep was shorter, lighter, and more fragmented, with bigger gaps versus controls on night two.
fMRI study found THC weakened brain activation in impulse control regions (right frontal, anterior cingulate) while CBD affected entirely different areas, independent of intoxication.
Blocking 2-AG breakdown with a MAGL inhibitor revealed hidden cannabinoid effects in mice, including evidence for cannabinoid receptors beyond the known CB1 and CB2.
CBD selectively normalized gut hypermotility in mice with intestinal inflammation without affecting normal movement, working through CB1 receptors and the FAAH enzyme.
Case report of a young man who had a heart attack with acute coronary thrombosis shortly after smoking marijuana, treated successfully with emergency angioplasty.
Simulated drug market study found cannabis demand was quality-sensitive, with users switching to alcohol when cannabis quality dropped, while alcohol demand was unaffected by quality changes.
Six plant cannabinoids activated the pain-sensing TRPA1 channel (CBC most potent at 60 nM) and blocked the cold-sensing TRPM8 channel, revealing non-CB1/CB2 mechanisms for pain relief.
Year-long study found ecstasy polydrug users showed mild cognitive decline while cannabis was paradoxically linked to faster brain processing speed on EEG measures.
Case report of an MS patient with tics, dystonia, and marijuana dependence who improved across all symptoms on prescription dronabinol without experiencing the "high."
Review showed that the CB2 cannabinoid receptor on immune cells can directly suppress the autoreactive T cells that cause MS nerve damage, offering a potential non-psychoactive therapeutic target.
Olanzapine reversed THC-induced spatial memory impairment in rats by restoring hippocampal acetylcholine levels, while haloperidol had no effect at any dose tested.
National survey of 2,613 frequent cannabis users found 44% experienced clinically significant withdrawal symptoms, with identical rates among cannabis-only users, supporting its diagnostic recognition.
In mice, high-dose CBD unexpectedly amplified low-dose THC's behavioral effects by increasing CB1 receptor expression, challenging the assumption that CBD always counteracts THC.
Review of brain science behind cannabis addiction found that cannabinoid receptor systems undergo specific neuroadaptive changes with chronic use, overturning the notion that cannabis is non-addictive.
CBD suppressed T cell function through NFAT/AP-1 transcription factor disruption, and this occurred independently of both CB1 and CB2 cannabinoid receptors.
Mutating two adjacent CB1 receptor amino acids individually caused modest effects, but combining them caused a synergistic 50-fold loss in activation, revealing a critical signal transduction switch.
Brief review explained how the endocannabinoid system drives both food craving and fat storage, making CB1 receptor blockers potential anti-obesity drugs.
Meta-analysis of 30 trials found cannabinoids significantly outperformed older anti-nausea drugs for chemotherapy, with nearly half of 1,138 patients preferring cannabinoids despite more side effects.
Database analysis found fibroblasts and connective tissue cells express a full endocannabinoid system that may help regulate pain, inflammation, and tissue remodeling in muscles and fascia.
Systematic comparison found marijuana smoke contained up to 20x more ammonia and 3-5x more HCN than tobacco, but lower levels of some carcinogenic PAHs in mainstream smoke.
Review found limited evidence that cannabis use may worsen metabolic health in psychosis patients already at elevated cardiovascular risk, though long-term effects remain unclear.
fMRI study found cannabis users showed opposite brain patterns during memory: reduced frontal activation alongside increased parahippocampal activity, suggesting compensation for functional deficits.
Nerve agents that blocked both endocannabinoid enzymes simultaneously caused 10-fold brain cannabinoid increases and THC-like effects, revealing that dual blockade is fundamentally different from single enzyme inhibition.
Chemists created compounds that inhibit 2-AG production at nanomolar concentrations with high selectivity, providing precision tools for endocannabinoid research.
Comprehensive review found cannabinoids only produce reward in animals under narrow conditions, unlike other drugs of abuse, explaining their classification as "atypical" addictive substances.
13-year Norwegian study found frequent cannabis use linked to nearly triple the suicide attempt risk but not to depression, suggesting distinct pathways to suicidal behavior.
The definitive pharmacological characterization of THC, CBD, and THCV — showing that three molecules from the same plant have completely different, sometimes opposite, effects at cannabinoid receptors.
Crossover study found THC reduced the P300 attention brain wave, and a cannabis extract with CBD failed to reverse this effect, complicating the "CBD counteracts THC" narrative.
Comprehensive review found strong trial evidence for cannabinoid analgesics in neuropathic, cancer, and inflammatory pain, with Sativex already approved in Canada for two pain indications.
Proposed that migraine, fibromyalgia, and IBS may share a common cause: clinical endocannabinoid deficiency, providing a rationale for cannabinoid-based treatments.
Review found cannabis acutely helps sleep onset and deepens sleep but withdrawal causes insomnia and vivid dreams, while cocaine and ecstasy primarily disrupt sleep through arousal.
Review assembled evidence that the endocannabinoid system's major changes during puberty make adolescent brains especially vulnerable to lasting harm from cannabis exposure.
Pubertal rats given cannabinoids for 25 days showed persistent memory and social deficits lasting at least 15 days after stopping, while adult rats showed milder, more reversible effects.
Mice on high-fat diet showed tissue-specific endocannabinoid changes: increased levels in the pancreas (enzyme redistribution) and decreased levels in subcutaneous fat.
Comprehensive catalog found extensive FAAH inhibitor families but few selective MAGL inhibitors, highlighting a critical gap in the endocannabinoid research toolkit.
Review found CB1 receptor antagonists show metabolic benefits for obesity but psychiatric side effects limit use, proposing "neutral antagonists" as a safer next-generation approach.
Historical review traced medical cannabis from ancient times through US criminalization (1937, against AMA advice) to modern endocannabinoid science supporting pain, spasticity, and inflammation applications.
Chart review of 139 medical cannabis patients found 88% had multiple pain conditions (most commonly myofascial and neuropathic pain) and 37% faced significant access barriers despite legal authorization.
Review mapped the genetics of cannabis disorders: linkage regions on seven chromosomes and candidate genes in both the cannabinoid system (CNR1, FAAH, MGLL) and general addiction pathways.
Twin study developed a 50% heritable alcohol consumption measure that correlated with cannabis and nicotine use, supporting shared genetic vulnerability across substances.
Among 3,427 young women, those who used cannabis and tobacco simultaneously had 1.6x higher cannabis abuse risk, driven by environment (31%) rather than genetics (0%).
CBD enhanced glycine receptor function at low micromolar concentrations and directly activated them at higher concentrations, providing a non-cannabinoid mechanism for pain relief.
Critical review found CB1 antagonists for obesity achieved weight loss no better than existing drugs while carrying serious psychiatric side effects, questioning the approach's clinical value.
Survey of Nigerian prison inmates found 7% current cannabis use with 71% heavy users, rates barely lower than pre-imprisonment, and cannabis was uniquely associated with criminal history patterns.
Crossover trial of 17 cannabis-naive MS patients found Sativex caused no psychiatric problems or cognitive decline at therapeutic doses, though higher THC blood levels correlated with subtle psychological symptom scores.
THC disrupted brain activation in the parahippocampal gyrus and ventrostriatum during verbal learning, with ventrostriatal changes correlating with psychotic symptoms. CBD had no such effects.
A review found that all classes of cannabinoids show anti-inflammatory activity, potentially through promoting inflammation resolution rather than blocking its initiation.
In 20 MS patients, Sativex did not improve spasticity on clinical or neurophysiological measures and did not alter endocannabinoid system markers in peripheral blood.
Frequent use and anxiety often appear together, but this 2009 review could not pin down cause and effect.
Among 1,779 adolescents in substance abuse treatment, those who continued or started smoking cigarettes had significantly higher odds of relapsing on marijuana and alcohol at 12 months.